AI could revolutionise pharma compound synthesis
pharmaphorum
JANUARY 15, 2024
Researchers at the University of Cambridge and Pfizer have developed an AI-powered approach to make it easier to design and make pharma molecules
Sat.Jan 13, 2024 - Fri.Jan 19, 2024
118 
Former Pfizer statistician found guilty of insider trading on Paxlovid trial results
Fierce Pharma
JANUARY 19, 2024
A jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in federal court in the Southern District of New York. | A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Ex-Pfizer Employee Convicted for Insider Trades Ahead of Positive Paxlovid Data
MedCity News
JANUARY 19, 2024
The former Pfizer statistician worked on the clinical trial for the Covid-19 drug Paxlovid. A jury found the employee guilty of insider trading for transactions made before clinical data for the antiviral were publicly announced.
Three ways research offices can lead researchers to more funding
Clarivate
JANUARY 19, 2024
Over half of research office leaders say researchers are disengaged. How can you close the gap to win more funding? In late 2023, Research Professional News, an editorially independent part of Clarivate , surveyed research office leaders and staff as well as researchers around the world, taking a close look at the challenges facing them today and in the future.
Women’s health gap estimated at $1trn in new report
pharmaphorum
JANUARY 17, 2024
The disparity in access to healthcare between women and men around the world is often talked about but has never been given a dollar value – until now.
After row with Hungary and Poland, Pfizer sues Romania over missed COVID vaccine payments
Fierce Pharma
JANUARY 19, 2024
Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
UK ATMP sector “robust”, research finds
European Pharmaceutical Review
JANUARY 18, 2024
An attractive destination for ATMP clinical trials Based on the Cell and Gene Therapy Catapult (CGT Catapult)’s recently published UK 2023 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database , the UK is an attractive location for ATMP clinical trials. This is largely due to the number of ongoing ATMP clinical trials in the UK remaining “largely stable” over the past three years.
New anti-smoking drug set for rapid NHS rollout
pharmaphorum
JANUARY 17, 2024
Oral cytisine therapy for smoking cessation from Consilient Health will launch in the UK next week, helping to alleviate a shortage of prescription drugs to help people quit
Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset
Fierce Pharma
JANUARY 19, 2024
More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnose | More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients.
9 Hot Takes from JPM24
MedCity News
JANUARY 15, 2024
I didn’t make it to this year’s J.P. Morgan Healthcare Conference in San Francisco, so I reached out to leaders from across the industry to hear how it went and learn about their takeaways from the event. This is a list of the nine most interesting responses that I received.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Keytruda Granted Latest FDA Approval in Cervical Cancer
Pharmaceutical Commerce
JANUARY 15, 2024
FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.
NICE backs Pfizer’s Talzenna for advanced breast cancer
pharmaphorum
JANUARY 18, 2024
Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.
Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts
Fierce Pharma
JANUARY 17, 2024
Bayer is launching a sweeping business overhaul as the German conglomerate sees “no viable alternative.” | Bayer is launching a sweeping business overhaul that will “come at the expense of many managerial employees,” as the German conglomerate sees “no viable alternative.
Deloitte: 7 Trends Shaping Healthcare and Life Sciences in 2024
MedCity News
JANUARY 19, 2024
AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
Pharmaceutical Commerce
JANUARY 18, 2024
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.
Roche bags EU okay for subcutaneous Tecentriq
pharmaphorum
JANUARY 16, 2024
Roche’s Tecentriq has become the first PD-1/PD-L1 inhibitor to be cleared in the EU in a subcutaneous form that will make dosing easier for patients and healthcare providers
Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia
Fierce Pharma
JANUARY 16, 2024
Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.
Boulder Care Extends Virtual Substance Use Disorder Treatment to Adolescents
MedCity News
JANUARY 16, 2024
As the opioid crisis grows for teens, Boulder Care has expanded its substance use disorder treatment to support adolescents. The company is starting its adolescent services in Washington with UnitedHealthcare Community Plan.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
MHRA approves ‘safer’ medicine alternative for rare disease
European Pharmaceutical Review
JANUARY 15, 2024
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree ® (vamorolone), as a safer alternative to corticosteroids, for Duchenne muscular dystrophy (DMD). “In addition to its anti-inflammatory efficacy, both the EMA and the MHRA recognise the benefits of treatment with Agamree for bone health and growth,” Dr Shabir Hasham, Chief Medical Officer of Santhera Pharmaceuticals shared.
Winners named in NHS healthcare inequality contest
pharmaphorum
JANUARY 18, 2024
AI-powered patient risk assessment company C2-Ai and the Sickle Cell Society have won an NHS contest to find solutions that can tackle health inequality
After Pfizer offers discount, NICE gives thumbs up to breast cancer drug Talzenna
Fierce Pharma
JANUARY 18, 2024
Six months after England’s National Institute for Health and Care Excellence (NICE) spurned Pfizer’s breast cancer treatment Talzenna (talazoparib) because it was not cost effective, the agency has | Six months after England’s National Institute for Health and Care Excellence spurned Pfizer’s breast cancer treatment Talzenna because it was not cost effective, the agency has reversed course following the company’s offer to slash the price.
More Than a Survey: How to Holistically Embrace the Patient Experience
MedCity News
JANUARY 16, 2024
Despite the challenges that healthcare providers face and declining patient experience scores, several effective strategies can enhance their work to improve the patient experience and sufficiently satisfy expectations for care.
Could novel antibiotic successfully treat a ‘priority 1 pathogen’?
European Pharmaceutical Review
JANUARY 19, 2024
According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. Currently in Phase I development , the antibiotic’s novel mechanism of action was showcased through its effectiveness against the pathogen in in vitro studies.
FDA clears AI skin cancer detection device from DermaSensor
pharmaphorum
JANUARY 18, 2024
Medtech company DermaSensor gets FDA approval for a handheld device, powered by AI, that can be used to detect skin cancer at the point of care
AstraZeneca adds to rare blood disease portfolio with world-first Voydeya approval in Japan
Fierce Pharma
JANUARY 19, 2024
A month after Novartis made its entry into the paroxysmal nocturnal haemoglobinuria (PNH) field, AstraZeneca’s newest contender Voydeya bolsters the company’s presence in the disease area with a wo | The drug bolsters the company's portfolio in paroxysmal nocturnal haemoglobinuria (PNH) just as the market heats up thanks to new competitors from Novartis and Apellis.
CMS Finalizes Rule Streamlining Prior Authorization Process
MedCity News
JANUARY 17, 2024
CMS finalized a rule on Wednesday that included set deadlines for affected payers to complete prior authorization requests. Several organizations came out in support of the rule.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
NICE recommends innovative breast cancer drug
European Pharmaceutical Review
JANUARY 19, 2024
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations. An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable,
Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO
pharmaphorum
JANUARY 17, 2024
The US patent office has invalidated the only Seagen patent cited in a lawsuit claiming infringement by Daiichi Sankyo’s breast cancer therapy Enhertu.
Senators threaten to subpoena CEO testimony while J&J, Merck claim retaliation amid IRA legal fight
Fierce Pharma
JANUARY 18, 2024
In its efforts to probe high U.S. drug prices, the Senate health committee has already heard from the heads of Moderna, Eli Lilly, Novo Nordisk and Sanofi. | The Senate Committee on Health, Education, Labor, and Pensions will vote on issuing subpoenas at the end of the month after the Johnson & Johnson and Merck CEOs refused to testify at an upcoming hearing.
AMA President: Medicare Physician Pay Cuts Will Have ‘Dire’ Impact if Not Reversed
MedCity News
JANUARY 17, 2024
The Medicare physician pay cuts that went into effect January 1 is a “disaster for the profession,” said Dr. Jesse Ehrenfeld, president of the AMA, during an interview at CES 2024. Getting the pay cut reversed is a top priority for the organization.
ABM Evolution: How Top Marketers Are Using Account-Based Strategies
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Let's personalize your content